ALNY - Alnylam Pharmaceuticals - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US02043Q1076

RNAi Therapeutics, Cardiovascular, Rare Diseases, Liver, Neurological

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in discovering, developing, and commercializing innovative medicines based on ribonucleic acid interference (RNAi) technology. This cutting-edge approach allows the company to create novel therapeutics that can potentially treat a wide range of diseases.

The company's marketed products include ONPATTRO (patisiran), which is used to treat the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. They also offer AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults, as well as GIVLAARI for the treatment of acute hepatic porphyria in adults. Additionally, their product OXLUMO is used to treat primary hyperoxaluria type 1.

Alnylam Pharmaceuticals has a robust pipeline of investigational therapies, including patisiran for the treatment of transthyretin amyloidosis with cardiomyopathy, cemdisiran for the treatment of complement-mediated diseases, and Belcesiran for the treatment of alpha-1 liver disease. They are also developing Elebsiran to treat chronic HBV infection, Zilebesiran to treat hypertension, and ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy. Furthermore, the company is working on ALN-HSD for the treatment of non-alcoholic steatohepatitis (NASH).

In addition to their internal research and development efforts, Alnylam Pharmaceuticals has formed strategic collaborations with leading biopharmaceutical companies, including Regeneron Pharmaceuticals, Inc. and Roche. These partnerships aim to discover, develop, and commercialize RNAi therapeutics for a range of diseases, including those affecting the eye and central nervous system. The company has also entered into license and collaboration agreements with Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc.

Founded in 2002, Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, and has established itself as a leader in the RNAi therapeutics space. For more information, please visit their website at https://www.alnylam.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for ALNY - Alnylam Pharmaceuticals  - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for ALNY - Alnylam Pharmaceuticals  - Stock & Dividends

ALNY Stock Overview

Market Cap in USD 31,244m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2004-05-28

ALNY Stock Ratings

Growth 5y 50.2
Fundamental -21.0
Dividend -
Rel. Performance vs Sector 1.45
Analysts 4.07/5
Fair Price Momentum 232.01 USD
Fair Price DCF 26.64 USD

ALNY Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

ALNY Growth Ratios

Growth 12m 15.28%
Growth Correlation 12m -32%
Growth Correlation 3m 70%
CAGR 5y 25.36%
CAGR/Mean DD 5y 1.52
Sharpe Ratio 12m 0.20
Alpha vs SP500 12m -5.95
Beta vs SP500 5y weekly 0.85
ValueRay RSI 64.66
Volatility GJR Garch 1y 39.12%
Price / SMA 50 26.76%
Price / SMA 200 38.76%
Current Volume 892.9k
Average Volume 20d 1940.2k

External Links for ALNY Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of ALNY stocks?
As of July 19, 2024, the stock is trading at USD 236.70 with a total of 892,886 shares traded.
Over the past week, the price has changed by -9.32%, over one month by +53.84%, over three months by +63.06% and over the past year by +17.50%.
What are the forecast for ALNY stock price target?
According to ValueRays Forecast Model, ALNY Alnylam Pharmaceuticals will be worth about 257 in July 2025. The stock is currently trading at 236.70. This means that the stock has a potential upside of +8.59%.
Issuer Forecast Upside
Wallstreet Target Price 244.6 3.32
Analysts Target Price 229.4 -3.09
ValueRay Target Price 257 8.59